[aftermathman]

yep its our old friend Prosavin and Oxford Biomedica.

Look at http://www.acnr.co.uk/2014/08/partic...in-gene-trial/

and boy does Prosavin look good.

However this has to be the most frustrating product on trial as it seems to have been stuck in the clinical trial process at "Phase I/II trial completed". Good news I hear you say, given the awful state of the PD drug pipeline this makes it a front runner ...

except ...

that it isn't.

IMHO this drug shows all that is wrong with pharma and the trial process. The senior management at Oxford continue to profit while nothing happens to bring the drug to market (or prove it doesn't work). None of the big charities seem inclined to invest in the product and it seems Oxford will not progress without a partner. Big pharma isn't that interested in dodgy gene therapy so no partner = no progress.

I remember the day (last year as I recall) when gene therapy was the great hope. Remember Neurologix, Ceregene, etc. What has happened now ? A few failures and its lights out on gene therapy for PD.

Lets at least find out if this thing works, at the moment it looks like a typical British product, all the innovation in the world but no idea how to get it to market.

Neil.